These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1444878)

  • 1. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
    Gasser T; Schwarz J; Arnold G; Trenkwalder C; Oertel WH
    Arch Neurol; 1992 Nov; 49(11):1131-4. PubMed ID: 1444878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute challenge with apomorphine and levodopa in Parkinsonism.
    Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
    Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
    Sharma JC; Macnamara L; Hasoon M; Vassallo M
    Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
    Grandas F; Gancher ST; Rodriguez M; Lera G; Nutt JG; Obeso JA
    Clin Neuropharmacol; 1992 Feb; 15(1):13-8. PubMed ID: 1576595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease.
    Müller T; Benz S; Börnke C; Russ H; Przuntek H
    J Neural Transm (Vienna); 2003 Jun; 110(6):603-9. PubMed ID: 12768356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM; Helscher RJ; Sattler AP
    Wien Klin Wochenschr; 1993; 105(16):472-5. PubMed ID: 8212705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apomorphine in Parkinson disease].
    Gilhus NE
    Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3166-9. PubMed ID: 1948940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.